ES2717446T3 - Péptidos derivados de ERK y usos de los mismos - Google Patents

Péptidos derivados de ERK y usos de los mismos Download PDF

Info

Publication number
ES2717446T3
ES2717446T3 ES14846055T ES14846055T ES2717446T3 ES 2717446 T3 ES2717446 T3 ES 2717446T3 ES 14846055 T ES14846055 T ES 14846055T ES 14846055 T ES14846055 T ES 14846055T ES 2717446 T3 ES2717446 T3 ES 2717446T3
Authority
ES
Spain
Prior art keywords
erk
peptides derived
peptides
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14846055T
Other languages
English (en)
Inventor
Rony Seger
Alexander Plotnikov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2717446T3 publication Critical patent/ES2717446T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14846055T 2013-09-17 2014-09-15 Péptidos derivados de ERK y usos de los mismos Active ES2717446T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878633P 2013-09-17 2013-09-17
PCT/IL2014/050822 WO2015040609A1 (en) 2013-09-17 2014-09-15 Erk-derived peptides and uses thereof

Publications (1)

Publication Number Publication Date
ES2717446T3 true ES2717446T3 (es) 2019-06-21

Family

ID=52688321

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14846055T Active ES2717446T3 (es) 2013-09-17 2014-09-15 Péptidos derivados de ERK y usos de los mismos

Country Status (4)

Country Link
US (2) US9695402B2 (es)
EP (1) EP3046929B1 (es)
ES (1) ES2717446T3 (es)
WO (1) WO2015040609A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2662036T3 (es) 2007-02-28 2018-04-05 Yeda Research And Development Company Limited Secuencias que se dirigen al núcleo
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
CN105566485A (zh) * 2015-12-29 2016-05-11 米佳 一种能靶向抑制epk信号通路的抗肿瘤多肽及其应用
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
EP3890727A1 (en) * 2018-12-03 2021-10-13 Yeda Research and Development Co. Ltd Inhibitors of erk nuclear translocation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5459036A (en) 1993-03-19 1995-10-17 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Extracellular signal-regulated kinase, sequences, and methods of production and use
AU2773695A (en) 1994-06-13 1996-01-05 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US6090784A (en) 1995-12-01 2000-07-18 Yale University RNA polymerase II peptides and methods of use
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
SK151599A3 (en) 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
BR9815493A (pt) 1997-07-21 2000-10-31 Pharmacia & Upjohn Ab Citólise dirigida de células-alvo, agentes e composições que causam citólise, e compostos que podem ser usados para produzir os agentes
CA2305370C (en) 1997-09-26 2006-11-28 Zentaris Gmbh Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
AU2228299A (en) 1998-01-14 1999-08-02 Board Of Regents Of The University Of Oklahoma, The Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen
AU5590999A (en) 1998-09-01 2000-03-21 Trustees Of The University Of Pennsylvania, The Peptide scaffolds for transfer of molecules into eukaryotic cells
US20040091966A1 (en) 1999-08-30 2004-05-13 Martin Zeidler Polypeptide regulation by conditional inteins
AUPR230500A0 (en) 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US20040253578A1 (en) 2001-04-02 2004-12-16 Roberts Radclyffe L. Dynamic action reference tools
US20030083261A1 (en) 2001-04-30 2003-05-01 Hongtao Yu Class of 12mer peptides that inhibit the function of the mitotic check point protein Mad2
WO2003070884A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
ES2662036T3 (es) 2007-02-28 2018-04-05 Yeda Research And Development Company Limited Secuencias que se dirigen al núcleo
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof

Also Published As

Publication number Publication date
US10240133B2 (en) 2019-03-26
EP3046929A1 (en) 2016-07-27
US9695402B2 (en) 2017-07-04
EP3046929B1 (en) 2019-01-16
WO2015040609A1 (en) 2015-03-26
US20170233702A1 (en) 2017-08-17
EP3046929A4 (en) 2017-02-08
WO2015040609A8 (en) 2015-04-23
US20160340655A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2016000981A1 (es) Formulaciones de estrigolactona y sus usos
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
DK4056212T3 (da) Autoinjektor
EP3804591C0 (en) SKIN CLEANSING DEVICE
HRP20190518T1 (hr) Tekuća zobena baza
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
EP3020856A4 (en) Elastic circular knitted fabric
DK2992104T3 (da) Fremgangsmåde til ekspression
BR112016011147A2 (pt) autoinjetor
ES1089856Y (es) Dispositivos de sujecion
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
DK3068505T3 (da) Spillesystem og -fremgangsmåde
CL2016001382A1 (es) Estabilidad de gel mejorada
EP2993194A4 (en) multiblock
LT3030259T (lt) Peptidai
IL240701A0 (en) Kntc2 peptides and vaccines containing the same
EP2978473A4 (en) AUTOMATIC RETRACTABLE SYRINGE
IL236690B (en) Ube2t peptides and vaccines containing the same
CL2017002226A1 (es) Etv2 y usos de los mismos
FI20135815L (fi) Teline
DE112013007428A5 (de) Komponententräger
HRP20180520T1 (hr) Suncobran
DK2821771T3 (da) Testfremgangsmåde
FR3003470B1 (fr) Autoinjecteur